Markets:

Overview

News

Currencies

International

Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

3.585 -0.035 (-0.97%)

Delayed Quote Updated: 1:48 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Prescription growth surged 45% in July after telehealth launch.

Via The Motley Fool

Topics Earnings

LENZ Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity...

Via MarketBeat

Topics Earnings

Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗

June 02, 2026

RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without...

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗

May 11, 2026

Via Chartmill

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗

March 24, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗

May 27, 2026

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office...

Via The Motley Fool

Topics Regulatory Compliance

LENZ Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption...

Via MarketBeat

Topics Earnings

Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗

May 11, 2026

Lenz (LENZ) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗

March 27, 2026

It failed to meet expectations for its final quarter of 2025.

Via The Motley Fool

Why Lenz Therapeutics Stock Crashed Today ↗

March 24, 2026

Is it time to throw away your reading glasses? Maybe not just yet.

Via The Motley Fool

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 23, 2026

LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗

November 05, 2025

LENZ Therapeutics Q3 2025 results show an 80% revenue beat and narrower loss as it launches its new FDA-approved vision treatment, VIZZ™.

Via Chartmill

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital...

Via MarketMinute

Topics Artificial Intelligence

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗

August 11, 2025

Via Benzinga

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗

August 01, 2025

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

Via Benzinga

Lenz (LENZ) Q2 Revenue Jumps 604% ↗

July 31, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 19, 2025

Via Benzinga

Earnings Scheduled For March 19, 2025 ↗

March 19, 2025

Via Benzinga

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships ↗

October 28, 2024

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

Via Benzinga

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

October 28, 2024

Via Benzinga

Why LENZ Therapeutics Stock Hit A New 52-Week High Today ↗

October 21, 2024

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application.

Via Benzinga

LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024 ↗

August 26, 2024

LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 10, 2024

Via Benzinga

ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday ↗

June 10, 2024

Via Benzinga

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says ↗

April 10, 2024

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.